Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by woolco999on Nov 19, 2021 7:38am
187 Views
Post# 34144536

30-40 cent range in January

30-40 cent range in JanuaryThis has been a brutal ride for so many.  A very high percentage have been dumping all year...and tax loss season will continue to keep this company well below its new valuation.

The results speak for themselves.  Getting the company turned around and positioned to take advantage of this new medical tech economy was harder than thought.  Needed to find the right leadership and mix of business approach to make it work.  They have arrived...but only new shareholders are going to reap most of the benefit as the ones that invested in 2020 were taken to the cleaners.  Results like below...will drive this to a very significant 9 figure valuation for sure.  I for one are going to keep the shares I have not dumped for tax loss...to gamble again that they have it right now.

Q3 Financial Highlights

  • Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021.

  • Gross profit was $10.5 million in the third quarter of 2021, up 1,288%, compared to $753,535 over the prior three-month period ending June 30, 2021.

  • Net income was $6.8 million in the third quarter of 2021, compared to a net loss of $8.7 million over the prior three-month period ending June 30, 2021.

  • Cash on balance sheet of $0.9 million and $1.9 million of debt at the end of third quarter 2021

<< Previous
Bullboard Posts
Next >>